Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaVânia Hungria, María-Victoria Mateos, Paweł Robak et al.|New England Journal of Medicine|2024Cited by 162
Thalidomide treatment of resistant or relapsed multiple myeloma patients.Marek Hus, Joanna Mańko, Anna Dmoszyńska et al.|PubMed|2001Cited by 85
Therapy‐related peripheral neuropathy in multiple myeloma patientsMarta Morawska, Marek Hus, Norbert Grząśko et al.|Hematological Oncology|2014Cited by 70
Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosisRuben A. Mesa, Srđan Verstovšek, Stephen T. Oh et al.|Leukemia|2022Cited by 63
Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myelomaMarek Hus, Anna Dmoszyńska, Norbert Grząśko et al.|Annals of Hematology|2011Cited by 62